Pharvaris is a clinical-stage pharmaceutical company focused on developing oral therapies for hereditary angioedema and other bradykinin B2 receptor-mediated diseases.
No data available
Are you interested in the impact of this company or this ETF?
It seems we haven't collected any data here yet. Just let us know and we will try to find data as soon as possible. Thank you for your feedback!